Cerulean Pharma reported $-8395000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Arrowhead Research ARWR:US $ -70306000 114.46M
Bayer BAYN:GR € 4762M 490M
Biocept BIOC:US $ -2.3M 0.02M
Brainstorm Cell Therapeutics BCLI:US $ -7.52M 2.12M
Cerulean Pharma CERU:US $ -8.4M 1.14M
Johnson & Johnson JNJ:US $ 8036M 1273M
Macrogenics MGNX:US $ -38931000 24.79M
Nektar Therapeutics NKTR:US $ -44.27M 67.08M
Perrigo Ordinary Shares PRGO:US $ 86.1M 6.5M
Pfizer PFE:US $ 12921M 1739M
Seattle Genetics SGEN:US $ -115.89M 0.06M
YTE INCY:US $ 276.8M 132.69M